Overview
Schrödinger Q3 2025 revenue rises 54% yr/yr, beating analyst expectations
Software revenue grows 28% yr/yr, reflecting demand for computational platform
Company lowers software revenue growth guidance, citing timing of pharma scale-up
Outlook
Schrödinger lowers 2025 software revenue growth guidance to 8%-13%
Company raises 2025 drug discovery revenue forecast to $49 mln-$52 mln
Schrödinger expects 2025 software gross margin of 73%-75%
Result Drivers
SOFTWARE DEMAND - Software revenue grew 28% due to increased demand for Schrödinger's computational platform
DRUG DISCOVERY REVENUE - Drug discovery revenue rose significantly due to upfront payments from ongoing collaborations
GUIDANCE ADJUSTMENT - Co lowered software revenue growth guidance due to timing of pharma scale-up opportunities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $54.30 mln | $51.50 mln (8 Analysts) |
Q3 Net Loss | -$32.80 mln | ||
Q3 Software Gross Margin | 73.00% | ||
Q3 Gross Profit | $28.04 mln | ||
Q3 Operating Expenses | $74 mln | ||
Q3 Software Revenue | $40.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Schrodinger Inc is $28.00, about 28.6% above its November 4 closing price of $19.99
Press Release: ID:nBw1jC2Qga
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)